Inherited genetics can influence safety and success of CAR-T cell therapy
New research published in Science Immunology reveals that a patient's inherited genetic makeup plays a critical role in how they respond to CAR-T cell therapy. This treatment, which reprograms immune cells to target cancer, has become a standard approach for certain blood cancers, such as lymphoma. However, not every patient experiences the same results or safety profile.
Investigators from the Mass General Brigham Cancer Institute, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute studied the genomes of over 200 patients. They identified specific gene variants that correlate with how well a person handles the treatment. For instance, variants in the STXBP2 gene were found to be linked to increased treatment-related toxicity. Conversely, variations in the ADAMTSL3 gene appeared to provide a protective effect against those same toxic side effects.
Beyond safety, the study highlighted how genetics influence the effectiveness of the therapy. Variants in the PTPN22 gene are associated with stronger CAR-T cell expansion, which is a key marker for successful treatment outcomes. Because every CAR-T product is manufactured using a patient's own cells, these genetic variations mean the treatment is essentially unique to each individual.
These findings provide a path for better donor selection and the potential design of more effective engineered cells. By understanding how individual genetics influence immune cell behavior, researchers aim to improve safety and patient outcomes for future immunotherapy applications.